Biontech Se Sponsored Adr (BNTX)
NASDAQ:BNTX
Want to see BNTX full AI Analyst Report?
BNTX Stock Chart & Stats
$102.92
-$4.73(-3.73%)
At close: 4:00 PM EST
$102.92
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$79.52 - $124.00
Previous CloseN/A
Volume316.50K
Average Volume (3M)1.05M
Market Cap
$22.90B
Enterprise Value$11.13B
Total Cash (Recent Filing)$14.65B
Total Debt (Recent Filing)$303.12M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 04, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding252,884,260
10 Day Avg. Volume1,235,680
30 Day Avg. Volume1,053,128
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue3.98
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda-15.79
Forecast
1Y Price Target
$127.36Price Target Upside23.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.63
Revenue Forecast (FY)$2.17B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity create durable financial optionality: BioNTech can fund multi-year, high-cost oncology development, absorb trial setbacks, and pursue strategic deals or manufacturing consolidation without immediate financing stress, supporting execution over the next 2–6 months and beyond.
Improving Free Cash FlowPositive free cash flow in 2025 and TTM signals the company can increasingly fund operations and late-stage trials internally. That reduces dilution risk and provides a steady funding base for commercialization investments and milestone-driven programs over the medium term, despite historic volatility.
Late-stage Oncology Pipeline BreadthA broad, late-stage oncology slate with thousands enrolled and multiple Phase 3 programs materially increases the probability of near- to medium-term new product approvals. Successful readouts would diversify revenue beyond COVID franchises and structurally transform BioNTech toward a sustainable multi-product commercial company.
Bears Say
2026 Revenue Decline GuidanceA guided material revenue drop reflects post-pandemic normalization and reduced COVID franchise contribution. That lowers near-term top-line cover for rising R&D and SG&A, forcing reliance on pipeline catalysts and cash reserves to bridge the commercialization gap over the next 2–6 months.
Deteriorated Profitability ProfileHigh gross margins insulated by COVID-era product mix are now offset by elevated operating spend. Until new oncology revenues ramp, persistent negative operating and net margins will pressure returns and could limit reinvestment flexibility, making near-term profitability recovery uncertain.
Founders' Transition And Execution RiskA planned leadership and scientific transition during a catalyst-rich period raises execution risk: loss of founding scientific leaders could affect strategic continuity, partner relationships and trial prioritization. Operational handover complexity may strain commercialization readiness in the medium term.
BioNTech SE News
BNTX FAQ
What was Biontech Se Sponsored Adr’s price range in the past 12 months?
Biontech Se Sponsored Adr lowest stock price was $79.52 and its highest was $124.00 in the past 12 months.
What is Biontech Se Sponsored Adr’s market cap?
Biontech Se Sponsored Adr’s market cap is $22.90B.
When is Biontech Se Sponsored Adr’s upcoming earnings report date?
Biontech Se Sponsored Adr’s upcoming earnings report date is Aug 04, 2026 which is in 50 days.
How were Biontech Se Sponsored Adr’s earnings last quarter?
Biontech Se Sponsored Adr released its earnings results on May 05, 2026. The company reported -$2.446 earnings per share for the quarter, beating the consensus estimate of -$2.559 by $0.113.
Is Biontech Se Sponsored Adr overvalued?
According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued.
Does Biontech Se Sponsored Adr pay dividends?
Biontech Se Sponsored Adr pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on Biontech Se Sponsored Adr dividends here
What is Biontech Se Sponsored Adr’s EPS estimate?
Biontech Se Sponsored Adr’s EPS estimate is -2.45.
How many shares outstanding does Biontech Se Sponsored Adr have?
Biontech Se Sponsored Adr has 252,884,260 shares outstanding.
What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?
Biontech Se Sponsored Adr reported an EPS of -$2.446 in its last earnings report, beating expectations of -$2.559. Following the earnings report the stock price went down -3.875%.
Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?
Currently, no hedge funds are holding shares in BNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.36 (23.74% Upside)
$127.36 (23.74% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 102.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.70%
12-Months-Change
Fundamentals
Return on Equity
-6.67%
Trailing 12-Months
Asset Growth
6.12%
Trailing 12-Months
Company Description
Biontech Se Sponsored Adr
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
BNTX Company Deck
BNTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented a constructive picture: BioNTech outperformed its raised 2025 guidance, preserved a very strong cash position (EUR 17.2 billion), advanced a broad late-stage oncology pipeline with multiple planned readouts in 2026–2030, and executed strategic deals to derisk programs. Offsetting this, management guided materially lower revenues for 2026 (EUR 2.0–2.3bn vs EUR 2.9bn in 2025), highlighted near-term increases in R&D and SG&A to support oncology launches, reported an adjusted net loss (EUR 117m) and disclosed a trial discontinuation in one indication. The founders' planned transition to a new company introduces execution uncertainty but is framed as an orderly process through end-2026. On balance, the positive operational progress, portfolio de-risking and very strong liquidity outweigh the near-term revenue headwinds and costs.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$127.36
▲(23.74% Upside)
Technical Analysis
Ownership Overview
0.50% Insiders
7.15% Mutual Funds
10.24% Other Institutional Investors
81.03% Public Companies and Individual Investors